Answers are grounded in this paper and cite their sources.
KS-IRIS incidence and mortality are higher in SSA than in the UK. This is largely explained by the more advanced Kaposi sarcoma disease and lower chemotherapy availability. KS-IRIS is a major contributor to Kaposi sarcoma-associated mortality in Africa. Our results support the need to increase awareness on KS-IRIS, encourage earlier presentation, referral and diagnosis of Kaposi sarcoma, and advocate on access to systemic chemotherapy in Africa.
No takes yet. Share an insight, caveat, or question.
Letang et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: